Danaher Co. (NYSE:DHR) Shares Bought by Prosperity Consulting Group LLC

Prosperity Consulting Group LLC increased its holdings in Danaher Co. (NYSE:DHRFree Report) by 14.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 1,408 shares of the conglomerate’s stock after buying an additional 173 shares during the period. Prosperity Consulting Group LLC’s holdings in Danaher were worth $352,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. Wellington Management Group LLP raised its position in shares of Danaher by 12.0% during the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after purchasing an additional 2,998,161 shares during the period. Price T Rowe Associates Inc. MD increased its position in Danaher by 10.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after buying an additional 1,619,586 shares during the period. Capital International Investors lifted its stake in Danaher by 9.1% in the fourth quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after buying an additional 1,334,781 shares during the last quarter. Norges Bank bought a new position in shares of Danaher during the fourth quarter worth about $1,752,382,000. Finally, Franklin Resources Inc. grew its position in shares of Danaher by 6.4% during the fourth quarter. Franklin Resources Inc. now owns 6,620,170 shares of the conglomerate’s stock worth $1,531,510,000 after acquiring an additional 395,498 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In other Danaher news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the transaction, the director now directly owns 116,202 shares in the company, valued at approximately $28,304,483.16. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other Danaher news, Director Alan G. Spoon sold 708 shares of the firm’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the sale, the director now directly owns 116,202 shares in the company, valued at approximately $28,304,483.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Brian W. Ellis sold 4,000 shares of the company’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total value of $1,000,040.00. Following the completion of the transaction, the senior vice president now owns 29,830 shares in the company, valued at approximately $7,457,798.30. The disclosure for this sale can be found here. In the last 90 days, insiders sold 148,783 shares of company stock worth $37,536,717. 10.90% of the stock is owned by corporate insiders.

Danaher Price Performance

NYSE DHR opened at $239.25 on Friday. The stock has a market capitalization of $177.21 billion, a P/E ratio of 40.55, a P/E/G ratio of 3.66 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The business’s fifty day moving average is $255.41 and its two-hundred day moving average is $247.07. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $269.11.

Danaher (NYSE:DHRGet Free Report) last announced its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating the consensus estimate of $1.72 by $0.20. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. Danaher’s revenue was down 2.6% compared to the same quarter last year. During the same period in the prior year, the business posted $2.36 earnings per share. On average, research analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on DHR shares. Robert W. Baird boosted their target price on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. TD Cowen increased their price objective on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Jefferies Financial Group started coverage on Danaher in a research report on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price on the stock. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and boosted their price target for the stock from $250.00 to $280.00 in a research report on Wednesday, April 17th. Finally, Barclays raised their price target on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a report on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $268.67.

Get Our Latest Stock Report on DHR

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

See Also

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.